{"id":6058,"date":"2023-02-13T09:47:59","date_gmt":"2023-02-13T08:47:59","guid":{"rendered":"https:\/\/blog.caixaresearch.org\/?p=6058"},"modified":"2023-02-13T09:47:59","modified_gmt":"2023-02-13T08:47:59","slug":"que-son-les-terapies-car-t-contra-el-cancer-cronica","status":"publish","type":"post","link":"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/","title":{"rendered":"Qu\u00e8 s\u00f3n les ter\u00e0pies CAR-T contra el c\u00e0ncer?"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/-KRw3HgEa5Q\" width=\"400\" height=\"225\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><span data-mce-type=\"bookmark\" style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" class=\"mce_SELRES_start\">\ufeff<\/span><\/iframe><\/p>\n<p><span style=\"font-weight: 300;\">La investigaci\u00f3 i la innovaci\u00f3 contra el c\u00e0ncer fa m\u00e9s de trenta anys que treballa en el desenvolupament de ter\u00e0pies que facin del nostre sistema immunitari un aliat molt m\u00e9s eficient per combatre les c\u00e8l\u00b7lules tumorals. Entre aquests tractaments, anomenats <\/span><i><span style=\"font-weight: 300;\">immunoter\u00e0pies<\/span><\/i><span style=\"font-weight: 300;\">, <\/span><span style=\"font-weight: 400;\">la<\/span><b> ter\u00e0pia CAR-T<\/b><span style=\"font-weight: 300;\"> (<\/span><i><span style=\"font-weight: 300;\">chimeric antigen receptor T-cell<\/span><\/i><span style=\"font-weight: 300;\"> o receptor d\u2019antigen quim\u00e8ric en limf\u00f2cits T) ha estat una de les m\u00e9s prometedores pel que fa a efic\u00e0cia.<\/span><\/p>\n<p><span style=\"font-weight: 300;\">Es tracta d\u2019un tipus de ter\u00e0pia en qu\u00e8 el pacient es converteix en el seu propi donant: es modifiquen gen\u00e8ticament els seus limf\u00f2cits T \u2014c\u00e8l\u00b7lules del sistema immunitari encarregades de la resposta immunit\u00e0ria antiinfecciosa i antitumoral\u2014\u00a0 perqu\u00e8 siguin m\u00e9s efectius a l\u2019hora de recon\u00e8ixer, atacar i destruir les c\u00e8l\u00b7lules canceroses.<\/span><\/p>\n<p><span style=\"font-weight: 300;\">Fa alguns dies, vam tenir el plaer de convidar al <\/span><a href=\"https:\/\/caixaimpulse.org\/ca\/debats-caixaimpulse-terapies-car-t\"><strong>Debat CaixaImpulse<\/strong><\/a><span style=\"font-weight: 300;\"> dos doctors pioners en el desenvolupament d\u2019aquest tipus de ter\u00e0pies a Europa:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 300;\" aria-level=\"1\"><b>El doctor Javier Briones<\/b><span style=\"font-weight: 300;\">, cap de la Unitat d\u2019Hematologia Cl\u00ednica i director del Grup d\u2019Investigaci\u00f3 d\u2019Immunoter\u00e0pia Cel\u00b7lular i Ter\u00e0pia G\u00e8nica de l\u2019Institut d\u2019Investigaci\u00f3 de l\u2019Hospital de Sant Pau (IIB-Sant Pau).<\/span><\/li>\n<li style=\"font-weight: 300;\" aria-level=\"1\"><b>El doctor Manel Juan<\/b><span style=\"font-weight: 300;\">, cap del Servei d\u2019Immunologia al Centre de Diagn\u00f2stic Biom\u00e8dic (CDB) de l\u2019Hospital Cl\u00ednic (HCB)-IDIBAPS i responsable de la plataforma de ter\u00e0pies avan\u00e7ades entre l\u2019Hospital Sant Joan de D\u00e9u i l\u2019Hospital Cl\u00ednic.\u00a0<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 300;\">A continuaci\u00f3 aportem algunes de les idees clau sobre les ter\u00e0pies CAR-T que els ponents van tractar durant el debat:<\/span><\/p>\n<p><b>En quin tipus de c\u00e0ncers s\u2019est\u00e0 aplicant la ter\u00e0pia CAR-T?<\/b><\/p>\n<p><span style=\"font-weight: 300;\">\u00abHa funcionat molt b\u00e9 en tumors hematol\u00f2gics \u2014que afecten la sang, la medul\u00b7la \u00f2ssia i els ganglis limf\u00e0tics\u2014, per\u00f2 en el cas dels tumors s\u00f2lids, com el de mama, el de c\u00f2lon o el de p\u00e0ncrees, la seva estructura m\u00e9s compacta dificulta l\u2019arribada dels limf\u00f2cits al teixit. No obstant aix\u00f2, la ter\u00e0pia CAR-T podria i hauria d\u2019arribar a aplicar-se tamb\u00e9 a tumors s\u00f2lids en un futur\u00bb. Manuel Juan<\/span><\/p>\n<p><b>Les ter\u00e0pies CAR-T s\u00f3n dins el sistema de salut nacional espanyol?<\/b><\/p>\n<p><span style=\"font-weight: 300;\">\u00abS\u00ed, fa m\u00e9s de cinc anys es va aprovar un pla d\u2019abordatge que va donar la possibilitat a les farmac\u00e8utiques, i fins i tot als centres d\u2019investigaci\u00f3 de l\u2019entorn acad\u00e8mic, de desenvolupar productes de ter\u00e0pia CAR-T de manera comercial\u00bb. Manel Juan<\/span><\/p>\n<p><span style=\"font-weight: 300;\">\u00abCada vegada es van sumant nous centres acreditats per a desenvolupar i administrar aquestes ter\u00e0pies, i ja en tenim m\u00e9s d&#8217;una dotzena a Espanya. Aquests pr\u00e0cticament cobreixen tot el territori espanyol, de manera que no hi ha cap pacient amb indicaci\u00f3 de rebre aquest tipus de ter\u00e0pia que es quedi sense rebre-la\u00bb. Javier Briones<\/span><\/p>\n<p><b>Quin \u00e9s el cost d\u2019aquest tipus de ter\u00e0pies?<\/b><\/p>\n<p><span style=\"font-weight: 300;\">\u00abEs troben en la zona m\u00e9s alta de cost terap\u00e8utic, per\u00f2 de moment els costos s\u00f3n assumits en gran mesura pel sistema p\u00fablic de salut. En el cas de les ter\u00e0pies CAR-T acad\u00e8miques \u2014aquelles que no s&#8217;han desenvolupat en una empresa privada, sin\u00f3 en l&#8217;entorn d&#8217;una instituci\u00f3 sense \u00e0nim de lucre\u2014 el seu cost sol ser m\u00e9s controlable\u00bb. Manel Juan.\u00a0<\/span><\/p>\n<p><b>Quin \u00e9s l\u2019aspecte revolucionari d\u2019aquest tipus de ter\u00e0pies?<\/b><\/p>\n<p><span style=\"font-weight: 300;\">\u00abUn aspecte revolucionari de les immunoter\u00e0pies \u00e9s que aprofiten les virtuts del sistema immunitari per combatre el tumor\u00bb. <\/span><span style=\"font-weight: 300;\">Manel Juan<\/span><\/p>\n<p><span style=\"font-weight: 300;\">\u00abFa m\u00e9s de trenta anys que investiguem en ter\u00e0pies cel\u00b7lulars i g\u00e8niques contra el c\u00e0ncer, i la que ha tingut un \u00e8xit m\u00e9s important pel que fa a efic\u00e0cia \u00e9s la ter\u00e0pia CAR-T\u00bb. <\/span><span style=\"font-weight: 300;\">Javier Briones<\/span><\/p>\n<p><b>En quins pacients s\u2019utilitzen les ter\u00e0pies CAR-T?<\/b><\/p>\n<p><span style=\"font-weight: 300;\">\u00abS\u2019utilitzen en pacients que es troben en estats avan\u00e7ats de la malaltia, que no han resp\u00f2s als tractaments convencionals de quimioter\u00e0pia i immunoter\u00e0pia. <\/span><span style=\"font-weight: 300;\">Actualment, tot i que les ter\u00e0pies CAR-T es troben en tercera l\u00ednia de tractament a Espanya, ja hi ha estudis, i fins i tot algunes <\/span><span style=\"font-weight: 300;\">ter\u00e0pies <\/span><span style=\"font-weight: 300;\">aprovades als Estats Units, que es troben en segona l\u00ednia<\/span><span style=\"font-weight: 300;\">\u00bb. Javier Briones.<\/span><\/p>\n<p><b>Quins reptes queden pendents?<\/b><\/p>\n<p><span style=\"font-weight: 300;\">\u00abUn dels problemes de les ter\u00e0pies CAR-T \u00e9s que, tot i ser m\u00e9s espec\u00edfiques que els tractaments convencionals, el sistema immunitari es pot dirigir a una mol\u00e8cula que no \u00e9s exclusiva del tumor \u2014c\u00e8l\u00b7lules sanes\u2014 i aix\u00f2 pot generar efectes adversos. Encara n\u2019hem de millorar l\u2019especificitat. El sistema immunitari \u00e9s molt complex i ens falten biomarcadors m\u00e9s espec\u00edfics\u00bb. Manel Juan.<\/span><\/p>\n<p><span style=\"font-weight: 300;\">\u00abL&#8217;increment de pacients als quals s&#8217;administra la ter\u00e0pia CAR-T en aquests \u00faltims tres anys ha estat exponencial i, sens dubte, cada vegada tindrem m\u00e9s ter\u00e0pies d&#8217;aquest tipus. Aix\u00f2 s\u00ed, caldr\u00e0 ser prudents i comprovar la seva efic\u00e0cia en diferents tipus de c\u00e0ncers\u00bb. Javier Briones.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><b>Si vols veure el debat complet, recupera\u2019l <a href=\"https:\/\/caixaimpulse.org\/ca\/debats-caixaimpulse-terapies-car-t\">aqu\u00ed<\/a>.<\/b><\/p>\n<p>&nbsp;<\/p>\n<p>Llegeix la cr\u00f2nica d\u2019altres debats:<\/p>\n<ul>\n<li><a href=\"https:\/\/caixaimpulse.org\/ca\/debats-caixaimpulse-covid-19-persistent\">COVID-19 persistent: qu\u00e8 en sabem?<\/a> Amb Lourdes Mateu (Hospital Germans Trias i Pujol i UAB) i Gema Maria Lled\u00f3 (Hospital Cl\u00ednic Barcelona). 23\/11\/22<\/li>\n<li><a href=\"https:\/\/blog.caixaresearch.org\/ca\/nutricio-i-cancer-la-importancia-de-la-prevencio\/\">Nutrici\u00f3 i c\u00e0ncer: la import\u00e0ncia de la prevenci\u00f3<\/a>. Amb Marina Poll\u00e1n\u00a0(CNE-ISCIII i CIBERESP) i Marcos Malumbres (CNIO). 27\/10\/22<\/li>\n<li><a href=\"https:\/\/blog.caixaresearch.org\/ca\/com-percep-el-cervell-el-mon-i-genera-records-2\/\">Com percep el cervell el m\u00f3n i genera records?<\/a> Amb el doctor Josep Dalmau (IDIBAPS &#8211; Hospital Cl\u00ednic de Barcelona) i la doctora Guillermina L\u00f3pez-Bendito (Institut de Neuroci\u00e8ncies d\u2019Alacant &#8211; CSIC). 21\/06\/22<\/li>\n<li><a href=\"https:\/\/blog.caixaresearch.org\/ca\/curar-la-ceguesa-tractar-la-retina-per-restaurar-la-visio-2\/\" target=\"_blank\" rel=\"noopener\">Curar la ceguesa: tractar la retina per restaurar la visi\u00f3.<\/a>\u00a0Amb la doctora Maria Pia Cosma (ICREA i CRG) i el doctor Jos\u00e9 Antonio Garrido (ICREA i ICN2). 25\/05\/22<\/li>\n<li><a href=\"https:\/\/blog.caixaresearch.org\/ca\/es-possible-crear-una-vacuna-universal-per-a-malalties-infeccioses-croniques-2\/\" target=\"_blank\" rel=\"noopener\">\u00c9s possible crear una vacuna universal per a malalties infeccioses cr\u00f2niques?<\/a>\u00a0Amb el doctor Christian Brander (ICREA, IrsiCaixa, Aelix Therapeutics) i la doctora Valentina Casella (MELIS-UPF). 26\/04\/22<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/covid-19-com-hi-haurem-de-conviure-2\/\">COVID-19: Com hi haurem de conviure?<\/a>\u00a0Amb el doctor Antoni Trilla (Hospital Cl\u00ednic de Barcelona, UB i ISGlobal) i la doctora Clara Prats (UPC i IGTP). 23\/03\/22<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/fundacionlacaixa.org\/ca\/debats-caixaresearch-malalties-minoritaries\">Malalties minorit\u00e0ries: Per qu\u00e8 el 95\u00a0% no tenen tractament?<\/a>\u00a0Amb els doctors Pablo Lapunzina i V\u00edctor Mart\u00ednez Gonz\u00e1lez (CIBERER i IdiPAZ). 23\/02\/2022<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/cancer-infantil-moltes-malalties-sense-tractaments-especifics\/\">C\u00e0ncer infantil: moltes malalties sense tractaments espec\u00edfics<\/a>. Amb el doctor Jaume Mora (PCCB) i la doctora Ana Pati\u00f1o (Cl\u00ednica Universidad de Navarra). 24\/01\/2022<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/40-anos-de-sida-para-cuando-una-cura-o-una-vacuna\/\">40 anys de sida: Quan tindrem una cura o una vacuna?<\/a>\u00a0Amb el doctor Juli\u00e0 Blanco i la doctora Beatriz Mothe (IrsiCaixa). 29\/11\/2021<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/nadons-prematurs-extrems-augmentant-la-seva-supervivencia\/\">Nadons prematurs extrems: augmentant la seva superviv\u00e8ncia<\/a>. Amb el doctor Eduard Gratac\u00f3s (BCNatal) i la doctora Adelina Pellicer (H. U. La Paz). 17\/11\/2021<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/com-abordem-les-malalties-del-cor-primera-causa-de-mortalitat-mundial\/\">Com abordem les malalties del cor? Primera causa de mortalitat mundial<\/a>. Amb el doctor Valent\u00ed Fuster (CNIC), la doctora Judit Cubedo (GlyCardial Diagnostics) i la doctora Gloria Santos (Fundaci\u00f3 SHE). 29\/09\/2021<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/ela-una-malaltia-mortal-per-molt-de-temps\/\">ELA, una malaltia mortal\u2026 per molt de temps?<\/a>\u00a0Amb la doctora Carmen M. Fern\u00e1ndez-Martos (HNP) i el doctor Rub\u00e8n L\u00f3pez Vales (UBNeuro). 17\/06\/2021<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/podrem-curar-lobesitat-una-pandemia-del-segle-xxi\/\">Podrem curar l\u2019obesitat? Una pand\u00e8mia del segle\u00a0xxi<\/a>. Amb el doctor Miguel L\u00f3pez (CiMUS) i la doctora Sonia Fern\u00e1ndez Veledo (IISPV). 27\/05\/2021<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/nous-reptes-en-vacunacio-i-erradicacio-de-malalties\/\">Nou reptes en vacunaci\u00f3 i erradicaci\u00f3 de malalties<\/a>. Amb el doctor Pedro Alonso (OMS) i la doctora Regina Rabinovich (ISGlobal). 22\/04\/2021<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/leucemia-present-i-futur-dels-nous-tractaments\/\">Leuc\u00e8mia, present i futur dels nous tractaments<\/a>. Amb el doctor El\u00edas Campo (IDIBAPS) i la doctora Biola Javierre (Institut d\u2019Investigaci\u00f3 contra la Leuc\u00e8mia Josep Carreras). 25\/03\/2021<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/dones-en-ciencia-superant-estereotips-i-desigualtats\/\">Dones en ci\u00e8ncia, superant estereotips i desigualtats<\/a>. Amb les doctores Blanca Fuentes (IdiPAZ), Carmen Gil (CIB-CSIC), Almudena Ramiro (CNIC), Mar\u00eda Soledad Soengas (CNIO) i Gemma Triola (ICAQ-CSIC). 11\/02\/2021<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/vacunes-la-gran-resposta-contra-la-covid-19\/\">Vacunes, la gran resposta contra la COVID-19<\/a>. Amb el doctor Mariano Esteban (CNB-CSIC) i la doctora Denise Naniche (ISGlobal). 26\/01\/2021<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/els-cervells-que-combaten-la-malaltia-dalzheimer\/\">Objectiu: prevenir la malaltia d\u2019Alzheimer. Un repte cient\u00edfic i social<\/a>. Amb la doctora Merc\u00e8 Boada (Fundaci\u00f3 ACE) i el doctor Arcadi Navarro (Fundaci\u00f3 Pasqual Maragall). 17\/11\/2020<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/cancer-cap-a-on-sorienten-les-noves-terapies\/\">C\u00e0ncer. Cap a on s\u2019orienten les noves ter\u00e0pies?<\/a>\u00a0Amb la doctora Mar\u00eda Blasco (CNIO) i el doctor Josep Tabernero (VHIO). 20\/10\/2020<\/li>\n<li aria-level=\"1\"><a href=\"https:\/\/blog.caixaresearch.org\/ca\/lexit-dels-tractaments-ja-disponibles-per-a-pacients-amb-covid-19\/\">L\u2019\u00e8xit dels tractaments ja disponibles per a pacients amb COVID-19<\/a>. Amb els doctors Bonaventura Clotet (IrsiCaixa) i Valent\u00ed Fuster (CNIO). 22\/09\/2020<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/-KRw3HgEa5Q\" width=\"400\" height=\"225\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\">\ufeff<\/iframe><\/p>\n<p>La investigaci\u00f3 i la innovaci\u00f3 contra el c\u00e0ncer fa m\u00e9s de trenta anys que treballa en el desenvolupament de ter\u00e0pies que facin del nostre sistema immunitari un aliat molt m\u00e9s eficient per combatre les c\u00e8l\u00b7lules tumorals. Entre aquests tractaments, anomenats <i>immunoter\u00e0pies<\/i>, la ter\u00e0pia CAR-T (<i>chimeric antigen receptor T-cell<\/i> o receptor d\u2019antigen quim\u00e8ric en limf\u00f2cits T) ha estat una de les m\u00e9s prometedores pel que fa a efic\u00e0cia.<\/p>\n<p>Es tracta d\u2019un tipus de ter\u00e0pia en qu\u00e8 el pacient es converteix en el seu propi donant: es modifiquen gen\u00e8ticament els seus limf\u00f2cits T \u2014c\u00e8l\u00b7lules del sistema immunitari encarregades de la resposta immunit\u00e0ria antiinfecciosa i antitumoral\u2014\u00a0 perqu\u00e8 siguin m\u00e9s efectius a l\u2019hora de recon\u00e8ixer,<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[340],"tags":[],"class_list":["post-6058","post","type-post","status-publish","format-standard","hentry","category-sense-categoria"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Qu\u00e8 s\u00f3n les ter\u00e0pies CAR-T contra el c\u00e0ncer? - Blog CaixaCi\u00e8ncia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qu\u00e8 s\u00f3n les ter\u00e0pies CAR-T contra el c\u00e0ncer? - Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"og:description\" content=\"\ufeff La investigaci\u00f3 i la innovaci\u00f3 contra el c\u00e0ncer fa m\u00e9s de trenta anys que treballa en el desenvolupament de ter\u00e0pies que facin del nostre sistema immunitari un aliat molt m\u00e9s eficient per combatre les c\u00e8l\u00b7lules tumorals. Entre aquests tractaments, anomenats immunoter\u00e0pies, la ter\u00e0pia CAR-T (chimeric antigen receptor T-cell o receptor d\u2019antigen quim\u00e8ric en limf\u00f2cits T) ha estat una de les m\u00e9s prometedores pel que fa a efic\u00e0cia. Es tracta d\u2019un tipus de ter\u00e0pia en qu\u00e8 el pacient es converteix en el seu propi donant: es modifiquen gen\u00e8ticament els seus limf\u00f2cits T \u2014c\u00e8l\u00b7lules del sistema immunitari encarregades de la resposta immunit\u00e0ria antiinfecciosa i antitumoral\u2014\u00a0 perqu\u00e8 siguin m\u00e9s efectius a l\u2019hora de recon\u00e8ixer,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-13T08:47:59+00:00\" \/>\n<meta name=\"author\" content=\"Ubikmedia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ubikmedia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/\",\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/\",\"name\":\"Qu\u00e8 s\u00f3n les ter\u00e0pies CAR-T contra el c\u00e0ncer? - Blog CaixaCi\u00e8ncia\",\"isPartOf\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\"},\"datePublished\":\"2023-02-13T08:47:59+00:00\",\"author\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\",\"url\":\"https:\/\/blog.caixaresearch.org\/\",\"name\":\"Blog CaixaCi\u00e8ncia\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.caixaresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca\",\"name\":\"Ubikmedia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g\",\"caption\":\"Ubikmedia\"},\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/author\/ubikmedia\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Qu\u00e8 s\u00f3n les ter\u00e0pies CAR-T contra el c\u00e0ncer? - Blog CaixaCi\u00e8ncia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/","og_locale":"ca_ES","og_type":"article","og_title":"Qu\u00e8 s\u00f3n les ter\u00e0pies CAR-T contra el c\u00e0ncer? - Blog CaixaCi\u00e8ncia","og_description":"\ufeff La investigaci\u00f3 i la innovaci\u00f3 contra el c\u00e0ncer fa m\u00e9s de trenta anys que treballa en el desenvolupament de ter\u00e0pies que facin del nostre sistema immunitari un aliat molt m\u00e9s eficient per combatre les c\u00e8l\u00b7lules tumorals. Entre aquests tractaments, anomenats immunoter\u00e0pies, la ter\u00e0pia CAR-T (chimeric antigen receptor T-cell o receptor d\u2019antigen quim\u00e8ric en limf\u00f2cits T) ha estat una de les m\u00e9s prometedores pel que fa a efic\u00e0cia. Es tracta d\u2019un tipus de ter\u00e0pia en qu\u00e8 el pacient es converteix en el seu propi donant: es modifiquen gen\u00e8ticament els seus limf\u00f2cits T \u2014c\u00e8l\u00b7lules del sistema immunitari encarregades de la resposta immunit\u00e0ria antiinfecciosa i antitumoral\u2014\u00a0 perqu\u00e8 siguin m\u00e9s efectius a l\u2019hora de recon\u00e8ixer,","og_url":"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/","og_site_name":"Blog CaixaCi\u00e8ncia","article_published_time":"2023-02-13T08:47:59+00:00","author":"Ubikmedia","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Ubikmedia","Temps estimat de lectura":"6 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/","url":"https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/","name":"Qu\u00e8 s\u00f3n les ter\u00e0pies CAR-T contra el c\u00e0ncer? - Blog CaixaCi\u00e8ncia","isPartOf":{"@id":"https:\/\/blog.caixaresearch.org\/#website"},"datePublished":"2023-02-13T08:47:59+00:00","author":{"@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.caixaresearch.org\/ca\/que-son-les-terapies-car-t-contra-el-cancer-cronica\/"]}]},{"@type":"WebSite","@id":"https:\/\/blog.caixaresearch.org\/#website","url":"https:\/\/blog.caixaresearch.org\/","name":"Blog CaixaCi\u00e8ncia","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.caixaresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca","name":"Ubikmedia","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g","caption":"Ubikmedia"},"url":"https:\/\/blog.caixaresearch.org\/ca\/author\/ubikmedia\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/6058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/comments?post=6058"}],"version-history":[{"count":12,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/6058\/revisions"}],"predecessor-version":[{"id":6152,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/6058\/revisions\/6152"}],"wp:attachment":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/media?parent=6058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/categories?post=6058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/tags?post=6058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}